Created by Joyce Soh
Australian lupus research, patient support, advocacy campaigns, and health policy news
Explore the latest content tracked by Lupus Australia Briefing
Reduced serum Sestrin-1 is associated with subclinical cardiovascular disease in lupus. Systemic lupus erythematosus carries increased cardiovascular morbidity even without overt clinical disease.
Lupus inflammatory signals reprogram neutrophils to release a less effective form of NET, weakening defense against Staphylococcus aureus. Common...
AbelZeta Pharma gained FDA clearance under its RMAT designation for a multi-center registrational Phase II trial of C-CAR168, a bispecific...
A Toronto Lupus Clinic study of 2264 SLE patients found 55.1% had arthritis, split into NDA (72.6%), JA (19.2%), and CIDA (8.1%).
A Phase 3 extension study is now recruiting to evaluate the long-term safety and tolerability of ianalumab in SLE patients who completed prior...
Roche has discontinued RG6382, its T-cell-engaging bispecific for systemic lupus erythematosus, after phase 1 data showed the molecule lacked the...
AbelZeta's C-CAR168, a dual CD20/BCMA CAR-T, earned EMA PRIME designation for refractory SLE with or without lupus nephritis.
Menopause can either worsen or ease lupus symptoms due to shifting estrogen levels, with no universal pattern across patients. The key message is...
A post hoc analysis shows belimumab doubles remission rates in SLE patients, reaching 18% modified DORIS remission versus 13% on placebo by week 52....
AbelZeta's dual CD20/BCMA CAR-T (C-CAR168) has secured EMA PRIME designation for refractory SLE, building on its FDA RMAT status and strong Phase I...
J&J is advancing nipocalimab for SLE.
New Australian research from Morand, Hoi and colleagues identifies distinct IgA autoantibody clusters in SLE patients, with one profile strongly tied...
Lupus nephritis patients diagnosed young face cardiovascular risks more than twice those of controls, with events possible in their 30s.
